瑞马唑仑的临床应用现状分析

崔 博1, 刘红 梅2, 齐贺 彬1, 赵林 枫1, 王宝 忠1
1.华北理工大学 2.唐山市工人医院

摘要

摘要：目的：瑞马唑仑(Remimazolam)是全球同步研发的 1. 1 类新药，其安全性、稳定性等优势已被全球多家药企认可，并于 2020 年 7 月正式获批
上市，打破了国内外临床镇静药物领域近 30 年无创新药上市的局面。随着瑞马唑仑的上市，因其相较于其他类型的镇静药有显著的优势，迅
速的走进了全球各个临床大夫的视野，也为麻醉医师的镇静药物选择提供了更多的选择，本文就瑞马唑仑目前在临床应用中的进展进行综述，
以期为临床治疗提供参考。

关键词

关键词：瑞马唑仑, 镇静药物，咪达唑仑 ,丙泊酚, 麻醉

参考

1] Sear, John W.. Challenges of bringing a new sedative to market!.

Current Opinion in Anaesthesiology 31(4):p 423-430, August 2018. |

DOI: 10.1097/ACO.0000000000000614

[2] Hu Q, Liu X, Wen C, Li D, Lei X. Remimazolam: An Updated

Review of a New Sedative and Anaesthetic. Drug Des Devel Ther. 2022

Nov 15;16:3957-3974. doi: 10.2147/DDDT.S384155. PMID: 36411859;

PMCID: PMC9675580.

[3] Noor N, Legendre R, Cloutet A, Chitneni A, Varrassi G, Kaye

AD. A comprehensive review of remimazolam for sedation. Health

Psychol Res. 2021 Jun 11;9(1):24514. doi: 10.52965/001c.24514. PMID:

34746482; PMCID: PMC8567764.

[4]Goudra, Basavana Gouda; Singh, Preet Mohinder1. Remimazolam:

The future of its sedative potential. Saudi Journal of Anaesthesia 8(3):p

388-391, Jul–Sep 2014. | DOI: 10.4103/1658-354X.136627

[5] 刘爱芬,卢悦淳.瑞马唑仑优势分析及在麻醉领域应用进展

[J].沈阳药科大学学报,2022,39(07):893-898.DOI:10.14066/j.cnki. cn21

-1349/r.2021.0679.

[6] Kim KM. Remimazolam: pharmacological characteristics and

clinical applications in anesthesiology. Anesth Pain Med (Seoul). 2022

Jan;17(1):1-11. doi: 10.17085/apm.21115. Epub 2022 Jan 20. PMID:

35139608; PMCID: PMC8841266.

[7]窦豆,栗亚茹,王璐,冯艺,姜陆洋.新型镇静药物瑞马唑仑的研

究进展[J].中国医药,2023,18(03):453-457.

[8]Liu G, Xiong Y. Analysis of Stress Response and Analgesic Effect

of Remazolam Combined with Etomidate in Painless Gastroenteroscopy.

Contrast Media Mol Imaging. 2022 Aug 3;2022:4863682. doi:

10.1155/2022/4863682. PMID: 35992545; PMCID: PMC9365612.

[9]王晓阁.丙泊酚临床应用进展[J].天津药学,2019,31(01):67-70.[10]Lingamchetty TN, Hosseini SA, Saadabadi A: Midazolam.

StatPearls [Internet], Treasure Island (FL); 2021

[11]Zhang L, Li C, Zhao C, You Y, Xu J. The comparison of

remimazolam and midazolam for the sedation of gastrointestinal

endoscopy: a meta-analysis of randomized controlled studies. Afr Health

Sci. 2022 Jun;22(2):384-391. doi: 10.4314/ahs.v22i2.44. PMID:

36407397; PMCID: PMC9652671.

[12]Zhao MJ, Hu HF, Li XL, Li XM, Wang DC, Kuang MJ. The

safety and efficacy between remimazolam and propofol in intravenous

anaesthesia of endoscopy operation: a systematic review and

meta-analysis. Int J Surg. 2023 Aug 3. doi:

10.1097/JS9.0000000000000638. Epub ahead of print. PMID:

37534687.

[13] Zhou YY, Yang ST, Duan KM, Bai ZH, Feng YF, Guo QL,

Cheng ZG, Wu H, Shangguan WN, Wu XM, Wang CH, Chai XQ, Xu GH,

Liu CM, Zhao GF, Chen C, Gao BA, Li LE, Zhang M, Ouyang W, Wang

SY. Efficacy and safety of remimazolam besylate in bronchoscopy for

adults: A multicenter, randomized, double-blind, positive-controlled

clinical study. Front Pharmacol. 2022 Oct 13;13:1005367. doi:

10.3389/fphar.2022.1005367. PMID: 36313321; PMCID: PMC9606208.

[14]Goyal R, Hasnain S, Mittal S, Shreevastava S. A randomized,

controlled trial to compare the efficacy and safety profile of a

dexmedetomidine-ketaminecombination with a propofol-fentanyl

combination for ERCP. Gastrointest Endosc 2016;83(5):928–33.

[15]Dong SA, Guo Y, Liu SS, Wu LL, Wu LN, Song K, Wang JH,

Chen HR, Li WZ, Li HX, Zhang L, Yu JB. A randomized, controlled

clinical trial comparing remimazolam to propofol when combined with

alfentanil for sedation during ERCP procedures. J Clin Anesth. 2023

Jun;86:111077. doi: 10.1016/j.jclinane.2023.111077. Epub 2023 Feb 9.

PMID: 36764022.

[16]Kim JY, Kim KN, Kim DW, Lim HJ, Lee BS. Effects of

dexmedetomidine sedation for magnetic resonance imaging in children:a

systematic review and meta-analysis. J Anesth. 2021.

https://doi.org/10.1007

/s00540-021-02946-4.

[17]Kamat PP, McCracken CE, Simon HK, Stormorken A, Mallory M,

Chumpitazi CE, Cravero JP. Trends in outpatient procedural sedation:

2007–2018. Pediatrics. 2020;145

[18]Mahmoud M, Mason KP. A forecast of relevant pediatric

sedation trends. Curr Opin Anaesthesiol. 2016;29:56–67

[19]1. Dai G, Pei L, Duan F, Liao M, Zhang Y, Zhu M, et al. Safety

and efficacy of remimazolam compared with propofol in induction of

general anesthesia. Minerva Anestesiol 2021; 87: 1073-9.

[20]Furuta M, Ito H, Yamazaki M. Anaesthetic management using

remimazolam in a patient with severe aortic stenosis: a case report. BMC

Anesthesiol 2021; 21: 202.

作者简介：作者简介：崔博，男，汉族，1997 年 10 月 18 日，

籍贯河南义马，学历：硕士研究生，专业：麻醉学

通讯作者简介：刘红梅 ，女，汉族，1972 年 6 月，籍贯：河

北唐山 学历：硕士研究生，专业：麻醉学